NINA Medical

Company Overview

Snapshot

Founded in January 2019 by Shmuel Ben-Ezra, Yoni Hertzberg, and Alex Volovick, NINA Medical operates with 1–10 employees. The company has secured $3.67 million in total capital across 9 funding rounds from 3 investors. In September 2025, NINA Medical received an extension to its Seed round, with.

Business overview

NINA Medical is a Health Tech & Life Sciences company pioneering a non-invasive treatment for Benign Prostatic Hyperplasia (BPH), a common prostate enlargement in aging men. The company's core technology utilizes ultrasound to provide the world's first truly non-invasive solution for both imaging and treating BPH within a urologist's office. This approach aims to enable early intervention without invasive procedures, serving the digital healthcare and medical devices sectors by offering a comfortable and precise alternative to traditional methods.

Strategic signal

NINA Medical is advancing its non-invasive BPH treatment with an ongoing first-in-human clinical study in an Israeli hospital. This development signals significant progress in validating its ultrasound-based technology, demonstrating its potential to disrupt the urology market by offering a comfortable and precise alternative to traditional invasive procedures. For investors, this indicates a critical step towards commercialization and market adoption in the medical devices and digital healthcare sectors.

Company Intelligence Q&A

What is NINA Medical's primary focus?

NINA Medical is focused on developing a non-invasive treatment for Benign Prostatic Hyperplasia (BPH), a common prostate enlargement in aging men. The company utilizes ultrasound technology for both imaging and treatment of BPH.

When did NINA Medical secure its most recent funding?

In September 2025, NINA Medical secured an extension to its Seed funding round. Rafael Holdings participated as a lead investor in this round.

What is the status of NINA Medical's clinical trials?

NINA Medical has demonstrated technological readiness through animal trials and a preliminary clinical study involving 20 patients. The company is currently conducting its first-in-human clinical study in an Israeli hospital.

Which investors have supported NINA Medical?

NINA Medical has received support from investors including Rafael Holdings.

What is the core technology behind NINA Medical's solution?

NINA Medical's core technology is based on non-invasive ultrasound, enabling both imaging and treatment of BPH. This approach allows for procedures to be performed in a urologist's office without the need for invasive surgery.